European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
2020· review· en· Leukemia· Medicine
aff
1,510
citations
Works
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.
Route
Field
Type
Language
Year range
to
Screen consensus
Sort
Flags
Screening evidence
Direct labels are sparse and unvalidated. Missing labels are unknown.
1 filter active
182 workspage 1 of 8
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
2018· article· en· The Lancet Oncology· Medicine
affno abstract
1,011
citations
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
2019· article· en· New England Journal of Medicine· Medicine
aff
841
citations
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
2018· article· en· Cell Reports· Medicine
aff
805
citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019· article· en· Journal of Clinical Oncology· Medicine
aff
772
citations
Lung adenocarcinoma promotion by air pollutants
2023· article· en· Nature· Environmental Science
afffund
761
citations
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
2018· article· en· Cancer Cell· Medicine
affno abstract
710
citations
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
2021· review· en· Journal of Thoracic Oncology· Biochemistry, Genetics and Molecular Biology
affno abstract
645
citations
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
2020· article· en· Nature Communications· Computer Science
fundno aff
541
citations
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
2016· article· en· The Lancet Oncology· Medicine
affno abstract
470
citations
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers
2018· article· en· Cell Reports· Biochemistry, Genetics and Molecular Biology
aff
393
citations
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
2018· article· en· Cell Reports· Biochemistry, Genetics and Molecular Biology
aff
366
citations
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019· article· en· Journal of Clinical Oncology· Medicine
aff
363
citations
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
2019· article· en· The Lancet Neurology· Medicine
afffundno abstract
311
citations
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
2020· review· en· Blood· Medicine
aff
293
citations
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
2021· article· en· Journal of Clinical Oncology· Medicine
aff
290
citations
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
2015· article· en· The Lancet Oncology· Medicine
affno abstract
281
citations
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
2021· article· en· Annals of Oncology· Medicine
aff
278
citations
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
2021· article· en· Clinical Cancer Research· Medicine
aff
263
citations
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
2021· article· en· Annals of Oncology· Medicine
aff
262
citations
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
2018· article· en· Leukemia· Immunology and Microbiology
aff
247
citations
Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base
2015· review· en· Journal of Clinical Oncology· Medicine
aff
246
citations
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
2021· article· en· The Lancet· Medicine
afffundno abstract
211
citations
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
2020· article· en· Blood· Medicine
aff
210
citations
Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study
2017· article· en· PLoS Medicine· Biochemistry, Genetics and Molecular Biology
fundno aff
186
citations